Xeris Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.
Xeris Pharmaceuticals has raised $30.0M across 2 funding rounds on record, the most recent an undisclosed round announced in Jun 2026.
Xeris Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Xeris Pharmaceuticals Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Xeris Pharmaceuticals raised $30.0M in a Post-IPO Equity announced in Jan 2022.
4.4 years later, an undisclosed round was announced in Jun 2026 with no disclosed amount.
Xeris Pharmaceuticals Founders and Leadership Team
Contact details for the Xeris Pharmaceuticals team: 1 of 2 have an email address on file.
Start 14-day free trial →Xeris Pharmaceuticals Funding Compared to Other Biotechnology Startups
Funded Startups Like Xeris Pharmaceuticals in Biotechnology and Chicago
Companies Similar to Xeris Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Xeris Pharmaceuticals Funding FAQs
What does Xeris Pharmaceuticals do?
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.
How much funding has Xeris Pharmaceuticals raised?
Xeris Pharmaceuticals has raised $30.0M across 2 rounds on record.
When did Xeris Pharmaceuticals last raise funding?
Xeris Pharmaceuticals' most recent funding round on record was announced in Jun 2026. The amount was not disclosed.
Who founded Xeris Pharmaceuticals?
FundedIQ lists John Shannon (Founder) at Xeris Pharmaceuticals.
Who is the CEO of Xeris Pharmaceuticals?
Paul Edick is listed as CEO at Xeris Pharmaceuticals.
Where is Xeris Pharmaceuticals headquartered?
Xeris Pharmaceuticals is based in Chicago, Illinois, United States.
How many employees does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals is in the 251-500 employee band.
About FundedIQ's Xeris Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Xeris Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.